CRISPR Therapeutics AG
ANTI-PTK7 IMMUNE CELL CANCER THERAPY
Last updated:
Abstract:
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as PTK7.sup.+ malignancies.
Status:
Application
Type:
Utility
Filling date:
7 Nov 2019
Issue date:
23 Sep 2021